Gypenoside XLIX Diabetic Retinopathy Experimental Data

Figshare hosts experimental data from a study investigating Gypenoside XLIX's protective effects against diabetic retinopathy. The dataset includes results from bioinformatics analysis, network pharmacology, and in vitro/in vivo assays measuring targets like PTGS2, ferroptosis markers, and tight junction integrity. It is a 367.1 KB ZIP file containing research data from Jiayi Gu, last updated in March 2026.

Use Cases

• Analyze the relationship between PTGS2 expression levels and ferroptosis markers like iron content and lipid peroxidation in the experimental data.
• Validate network pharmacology predictions by correlating identified shared targets (e.g., VEGFA, JUN, STAT3) with assay results from HG-stimulated ARPE-19 cells.
• Investigate the preservation of tight junction integrity in RPE cells as measured by immunofluorescence staining and Western blotting data.

Strengths

• Data is directly linked to a specific, peer-reviewed research study investigating a novel therapeutic mechanism for diabetic retinopathy.
• Includes multi-modal experimental results from bioinformatics, network pharmacology, and wet-lab assays (Western blot, immunofluorescence, iron/GSH assays).
• Dataset is openly available under a CC BY 4.0 license, facilitating reuse and verification.

Limitations

• The dataset is very small (367.1 KB), indicating it contains summary or processed results rather than raw, high-volume experimental data.
• Specific structure, column names, and row counts are unknown, complicating direct analysis without manual inspection of the file contents.
• Scope is limited to the specific experimental conditions and molecular pathways (PTGS2, ferroptosis) studied, not general diabetic retinopathy data.

Provenance

Source

Jiayi Gu, published on figshare.

Collection Method

Experimental data generated from combined bioinformatics, network pharmacology, and laboratory assays using diabetic mice and high glucose-stimulated ARPE-19 cells.

Freshness

Last updated March 2026, indicating it is a forward-dated publication from an ongoing or recently completed study.